Nexien BioPharma Inc. is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration ('FDA') pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. Nexien BioPharma's drug development strategy consists of: A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; B. Conducting "freedom to operate" investigations on these conditions; C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; D. Identifying the regulatory pathway with the FDA; and E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).